Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) has been all over the map over the past year. Cannabics Pharmaceuticals Inc was truly one of the most explosive plays on planet Earth in February, moving from $0.70 to $7.00 in just a couple weeks. It was a truly legendary move. And the problem with legendary moves is that they totally distort perception over any other time frame.
For example, CNBX is up 130% in the past 3 months. That’s great performance. It outpaces just 99.9% of stocks in the world right now. And yet, when you look at CNBX, you can’t help but see it as a popped bubble. And maybe it is. But that doesn’t have any bearing on where it can move from here. For those who aren’t very familiar with this stock, here is a quick overview to get you up to speed.
Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) bills itself as a U.S based public company dedicated to the development of Personalized Anti-Cancer and Palliative treatments.
Cannabics has been an exciting story in the space, with reports of a diagnostics technology supposedly positioned to revolutionize the way physicians identify disease in cancer patients in terms of a coordinated cannabinoids therapy program.
The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and academic research as well as current clinical studies underway at Rambam Hospital.
CNBX’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Its flagship product is Cannabics SR, a long-acting medical cannabis capsule that shows therapeutic effects as a palliative care therapy for cancer patients.
The Company’s scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics’ vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
According to company materials, “Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.”
Subscribe below and we’ll keep you on top of what’s happening before $CNBX stock makes its next move.
As noted above, the stock has been a massive roller coaster ride in the cannabis patch so far in 2017.
The ups and downs revolve around varying degrees to which the company’s proprietary technology — that appears to be some form of liquid biopsy diagnostics capable of producing a read on cancerous material refined toward a menu of treatments personalized for someone’s individual cancer type – is taken seriously, in terms of future therapeutic application.
That menu of treatments is all based on cannabinoid therapies provided by CNBX, naturally.
As far as recent catalysts, the company recently announced that it received the final report of the research held in the Technion Israel Institute of Technology, in which, according to the company, the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma).
Itamar Borochov, CEO of Cannabics Pharmaceuticals said, “The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine”.
Currently trading at a market capitalization of $244.6M, CNBX has a reported reserve ($567K) of cash on the books, which compares with virtually no total current liabilities.
Cannabics Pharmaceuticals Inc is pulling in trailing 12-month revenues of $101K. However, the company is seeing steep declines on the top line on a quarterly y/y basis, according to its latest report. One thing that always must be accounted for with this stock is the float size. It ran from $0.70 to $7.00 in part because of a squeeze on share supply (only 25M shares bouncing around out there). We will update the story again soon as further details emerge. For continuing coverage on shares of $CNBX stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!